BMRN · BioMarin Pharmaceutical Inc.
$59.33
+2.99% last session
End-of-day data · updated 2026-07-28
Market cap
$12B
Enterprise value
$11B
Trailing P/E
43.4
Forward P/E
9.4
Dividend yield
—
Beta
0.24
Avg volume
2M
Employees
3K
2D change
—
5D change
2.38%
10D change
1.14%
30D change
2.15%
60D change
5.20%
MTD change
4.24%
YTD change
1.41%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BMRN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-16
Latest call per bank · past 12 months
Citigroup
Buy$76.00
+28.1% vs priceRBC Capital
Sector Perform$62.00
+4.5% vs priceBank of America
Buy$80.00
+34.8% vs priceMorgan Stanley
Overweight$119
+100.6% vs priceBarclays
Overweight$105
+77.0% vs priceWells Fargo
Overweight$75.00
+26.4% vs priceJP Morgan
Overweight$119
+100.6% vs priceUBS
Buy$114
+92.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-16 | Citigroup | Maintains | Buy | $75.00 → $76.00 |
| 2026-07-07 | RBC Capital | Maintains | Sector Perform | $66.00 → $62.00 |
| 2026-05-22 | Canaccord Genuity | Maintains | Buy | $116 → $111 |
| 2026-05-19 | Bank of America | Maintains | Buy | $85.00 → $80.00 |
| 2026-05-19 | Citigroup | Initiates | Buy | $0.00 → $75.00 |
| 2026-05-18 | HC Wainwright & Co. | Maintains | Neutral | $55.00 → $50.00 |
| 2026-05-07 | Canaccord Genuity | Maintains | Buy | $104 → $116 |
| 2026-05-05 | Bernstein | Maintains | Outperform | $94.00 → $82.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 67 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.8% above the 50-day MA ($56.54).
- Price vs 200-day MA: Trading 10.5% above the 200-day MA ($56.15).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.04) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($64.08).
BMRN Price Chart
Loading chart for BMRN…
Fundamentals
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.